Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Alimta ® (pemetrexed for injection)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Alimta® (pemetrexed): Use in Patients With COVID-19 (Coronavirus disease 2019)
The use of pemetrexed in patients with COVID-19 has not been studied.
COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1
Lilly has not studied the use of pemetrexed in patients with COVID-19.
Treating physicians should assess the patient’s individual benefit/risk ratio considering the patient's signs and symptoms, prior medical history, concomitant medications, and other individual factors when making pemetrexed treatment decisions in the context of COVID-19. Adverse reactions of pemetrexed to be considered in particular, in the context of COVID-19, include
interstitial pneumonitis, and
increased risk of toxicity with ibuprofen in patients with renal impairment (see below for further information).2
Pemetrexed dose adjustments, made at the physician’s discretion, should follow the label. Supportive treatment should be provided as clinically indicated and patients monitored appropriately.3
Myelosuppression-Related Warnings and Precautions
Pemetrexed can cause severe myelosuppression (as manifested by neutropenia, thrombocytopenia, and anemia or pancytopenia) resulting in a requirement for transfusions and which may lead to neutropenic infection. The risk of myelosuppression is increased in patients who do not receive vitamin supplementation. Patients treated with pemetrexed must be instructed to take folic acid and vitamin B12 with pemetrexed as a prophylactic measure to reduce treatment-related toxicity.2
Interstitial Pneumonitis-Related Warnings and Precautions
Serious interstitial pneumonitis, including fatal cases, can occur with pemetrexed treatment2. Treatment should be withheld for acute onset of new or progressive unexplained pulmonary symptoms such as dyspnoea, cough, or fever pending diagnostic evaluation. If pneumonitis is confirmed, pemetrexed should be permanently discontinued.3
Potential Drug-Drug Interaction With Ibuprofen
Ibuprofen decreases the clearance of pemetrexed and increases its exposure (AUC). Patients with mild to moderate renal impairment (CrCl 45-79 mL/min)
have increased risk of pemetrexed toxicity, and
should avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of pemetrexed.2
Monitor patients more frequently for myelosuppression, renal, and GI toxicity if concomitant administration of ibuprofen cannot be avoided.2
Aspirin, administered in low to moderate doses (325 mg every 6 hours), does not affect the pharmacokinetics of pemetrexed.3
Additional Consideration From Clinical Trial Experience
Dyspnoea and cough are common adverse reactions (incidence ≥20%) of pemetrexed when administered in combination with pembrolizumab and platinum chemotherapy.3
Infectious Disease Resources for COVID-19
For the most current information regarding COVID-19, please refer to the following resources:
Coronavirus disease (COVID-19) outbreak on the regional office of the EU WHO
COVID-19 on the ECDC web page.
European Society for Medical Oncology (ESMO)
1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
4. Coronavirus disease (COVID-19) outbreak. World Health Organization Europe. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov
5. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china
6. European Society for Medical Oncology. Accessed March 23th. https://www.esmo.org/newsroom/covid-19-and-cancer/covid-19-useful-resources
7. [NICE] National Institute for Health and Care Excellence. Coronavirus (COVID-19). Available from: https://www.nice.org.uk/covid-19. Accessed 25 March 2020.
AUC = area under the curve
COVID-19 = coronavirus disease 2019
CrCl = creatinine clearance
ECDC = European Centre for Disease Prevention and Control
ESMO = European Society for Medical Oncology
EU WHO = World Health Organization (European regional office)
GI = gastrointestinal
Lilly = Eli Lilly and Company
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
Date of Last Review: 17 March 2020